Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
CRBP Stock Chart & Stats
$8.02
-$0.10(-0.79%)
At close: 4:00 PM EST
$8.02
-$0.10(-0.79%)
Day’s Range― - ―
52-Week Range$4.64 - $20.56
Previous CloseN/A
Volume39.58K
Average Volume (3M)503.64K
Market Cap
$140.78M
Enterprise Value$75.48M
Total Cash (Recent Filing)$103.98M
Total Debt (Recent Filing)$2.05M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Mar 17, 2026EPS Estimate
-1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding17,553,038
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-3.08
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.75
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$47.60Price Target Upside493.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.99
Revenue Forecast (FY)$5.33M
Bulls Say, Bears Say
Bulls Say
Efficacy SignalAnalyst highlights the 2.9% placebo-adjusted weight loss in the 150 mg arm as an encouraging early efficacy signal for CRB-913's obesity program.
Regulatory PathwayAnalyst notes that initiation of the placebo-controlled 12-week Phase 1b CANYON-1 trial and planned FDA discussions aiming to initiate pivotal studies by mid-2026 could accelerate CRB-913's clinical development timeline.
Safety ProfileAnalyst emphasizes the low incidence of adverse effects, including no observed neuropsychiatric events and minimal gastrointestinal side effects, as a meaningful safety differentiation versus earlier CB1-targeting drugs.
Bears Say
Neuropsychiatric RiskAnalyst cautions that lingering concern over potential neuropsychiatric events remains an overhang on the stock until larger trials confirm the absence of such effects.
Ocular Toxicity And Anxiety ReportsAnalyst flags ocular toxicity signals and multiple reports of anxiety among obese participants as safety uncertainties that could complicate regulatory review and commercial adoption.
Study Population LimitsAnalyst warns that the early weight-loss findings are difficult to interpret because the study enrolled predominantly healthy volunteers, limiting confidence in efficacy for the intended obese population.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $4.64 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $140.78M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Mar 17, 2026 which is in 10 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.657 by -$0.243.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.52.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 17,553,038 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.657. Following the earnings report the stock price went up 7.39%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.60 (493.52% Upside)
$47.60 (493.52% Upside)
Hedge Fund Trend
Decreased
By 15.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $446.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.19%
12-Months-Change
Fundamentals
Return on Equity
-55.65%
Trailing 12-Months
Asset Growth
-17.70%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Stock 12 Month Forecast
Average Price Target
$47.60
▲(493.52% Upside)
Technical Analysis
Ownership Overview
16.12% Insiders
3.94% Mutual Funds
9.40% Other Institutional Investors
64.96% Public Companies and
Individual Investors